Company intelligence / Profile preview

Vision Renu Taiwan

Taipei, Taiwan

Ownership: Private
Development stage: Other

Overview

Vision Renu is a clinical-stage biotechnology company headquartered in Taiwan, dedicated to developing innovative pharmacological solutions for ophthalmic conditions. The company's lead program, VR-101, is a topical eye drop formulation designed to treat presbyopia by temporarily improving near vision through pupil modulation. Currently in Phase 2 clinical development, VR-101 aims to offer a non-invasive and reversible alternative to corrective lenses or surgical interventions for the aging population. Vision Renu leverages its expertise in drug delivery and ophthalmology to address significant unmet needs in eye care.

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Vision Renu Taiwan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vision Renu Taiwan.

Explore the full profile